Latest News

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

A community-based initiative is proving that the path to heart health for Black men may not start in a physician’s office, but in the barber’s chair.

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the long COVID population.

CHAMPION-AF may potentially lead to a shared decision-making process between a lifetime of medication and a one-time catheter-based procedure.

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, provided practical insights for pharmacist to optimize the care of patients with cardio-kidney-metabolic conditions.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

The safety and effectiveness of marne-cel were established in an open-label, single-arm, multicenter phase 1/2 clinical trial.

Volunteer service strengthens pharmacists’ empathy, confidence, and communication, boosting patient trust, teamwork, and community connection.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.

FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo sues Hims & Hers and regulators hint at seizures.

Late-stage Lyme disease vaccine candidate VLA15 boosts immunization hopes as tick infections rise.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

The approval is a milestone for rare disease that has lacked treatments capable of crossing the blood-brain barrier and introduces a new class of agent that pharmacists will need to understand.